College of Medicine and Public Health

Activities

Activities per year 1974 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2031

• 298 Invited talk
• 202 Other
• 189 Oral presentation
• 83 Participating in a conference, workshop, ...
• 134 More
  • 30 Membership of network
  • 27 Membership of committee
  • 21 Organising a conference, workshop, ...
  • 17 Publication Peer-review
  • 15 Editorial work
  • 7 Visiting an external academic institution
  • 6 Consultancy
  • 4 Membership of board
  • 3 Examination
  • 2 Membership of council
  • 2 Converted from Research Output

Activities per year

Search results

• GoldFFX Basic User Training and Chemical Manifold Material Safety Data Sheet (MSDS) and Document Search Training

  Matthews, S. (Participant)

  4 Oct 2016

  Activity: Other activity types › Other

• Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23. PMID: 26698636 Clinical Trial.

  Morton, E. (Other)

  2016

  Activity: Other activity types › Other

• Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Am Heart J. 2016 Aug;178:176-84. doi: 10.1016/j.ahj.2016.05.012. Epub 2016 Jun 9. PMID: 27502866

  Morton, E. (Other)

  2016

  Activity: Other activity types › Other

• Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition. Ungar L, Rodriguez F, Mahaffey KW. Coron Artery Dis. 2016 Nov;27(7):604-15. doi: 10.1097/MCA.0000000000000409. PMID: 27398626 Review.

  Morton, E. (Other)

  2016

  Activity: Other activity types › Other

• Plasma PAFAH/PLA2G7 Genetic Variability, Cardiovascular Disease, and Clinical Trials. Karabina S, Ninio E. Enzymes. 2015;38:145-55. doi: 10.1016/bs.enz.2015.09.002. Epub 2015 Oct 17. PMID: 26612651

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. PMID: 26052984 Clinical Trial.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Vorapaxar in the secondary prevention of atherothrombosis. Tantry US, Liu F, Chen G, Gurbel PA. Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1293-305. doi: 10.1586/14779072.2015.1109447. Epub 2015 Nov 12. PMID: 26559689 Review.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Hassan M. Glob Cardiol Sci Pract. 2015 Jan 26;2015:6. doi: 10.5339/gcsp.2015.6. eCollection 2015. PMID: 25830150.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Royal Children's Hospital Internal Auditor Training

  Matthews, S. (Participant)

  1 Oct 2015

  Activity: Other activity types › Other

• Harmonising Age Pathology Parameters in Kids (HAPPI Kids)

  Matthews, S. (Participant)

  31 Dec 2015

  Activity: Other activity types › Other

• Story board and E-Collage for the Dignity in Mental Health Project, World Federation for Mental Health (WFMH).

  Lawn, S. (Participant)

  2015

  Activity: Other activity types › Other

• Development of an online screening tool to identify the needs of new clients and refer them to service

  Lawn, S. (Participant), Morello, A. (Participant), Oster, C. (Participant), Redpath, P. (Participant), Venning, A. (Participant), Cromarty, P. (Participant) & Drummond, A. (Participant)

  2015

  Activity: Other activity types › Other

• Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar. Serebruany VL, Fortmann SD, Kim MH. Cardiology. 2016;133(2):69-72. doi: 10.1159/000440798. Epub 2015 Oct 22. PMID: 26488178 Clinical Trial.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Redesigning TRACER trial after TRITON. Serebruany VL. Int J Cardiol. 2015 Oct 15;197:44-7. doi: 10.1016/j.ijcard.2015.06.020. Epub 2015 Jun 18. PMID: 26126053

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW. J Am Heart Assoc. 2015 Dec 15;4(12):e002546. doi: 10.1161/JAHA.115.002546. PMID: 26672080 Clinical Trial.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis. Diehl P, Bode C, Duerschmied D. Ther Clin Risk Manag. 2015 Aug 3;11:1133-8. doi: 10.2147/TCRM.S55469. eCollection 2015. PMID: 26346960. Review.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Vorapaxar for secondary stroke prevention: perspectives and obstacles. Serebruany VL, Kim MH, Fortmann SD, Hanley DF. Expert Rev Neurother. 2015;15(12):1377-82. doi: 10.1586/14737175.2015.1111761. Epub 2015 Nov 13. PMID: 26566105

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. Serebruany VL, Choi SY, Kim MH. Int J Cardiol. 2016 Feb 15;205:13-16. doi: 10.1016/j.ijcard.2015.12.001. Epub 2015 Dec 3. PMID: 26709134

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Am J Cardiol. 2015 May 15;115(10):1325-32. doi: 10.1016/j.amjcard.2015.02.043. Epub 2015 Feb 18. PMID: 25776457 Clinical Trial.

  Morton, E. (Other)

  2015

  Activity: Other activity types › Other

• Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, Moliterno DJ. Am J Cardiol. 2014 Sep 1;114(5):665-73. doi: 10.1016/j.amjcard.2014.05.054. Epub 2014 Jun 18. PMID: 25129064 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, Moliterno DJ, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW. Eur Heart J Acute Cardiovasc Care. 2014 Sep;3(3):246-56. doi: 10.1177/2048872614527838. Epub 2014 Mar 13. PMID: 24627331 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Am J Cardiol. 2014 Mar 15;113(6):936-44. doi: 10.1016/j.amjcard.2013.11.052. Epub 2013 Dec 25. PMID: 24444781 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, Moliterno DJ, Aylward PE, Mahaffey KW, Armstrong PW. J Am Heart Assoc. 2014 Jul 10;3(4):e001032. doi: 10.1161/JAHA.114.001032. PMID: 25012288. Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Work Health and Safety - Risk Management Module

  Matthews, S. (Participant)

  23 Sept 2014

  Activity: Other activity types › Other

• PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. J Thromb Thrombolysis. 2014 Nov;38(4):423-9. doi: 10.1007/s11239-014-1075-4. PMID: 24676931 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, Moliterno DJ, Van de Werf F, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW. J Am Coll Cardiol. 2014 Mar 25;63(11):1048-57. doi: 10.1016/j.jacc.2013.10.048. Epub 2013 Nov 21. PMID: 24211500 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Jones WS, Tricoci P, Huang Z, Moliterno DJ, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW. Am Heart J. 2014 Oct;168(4):588-96. doi: 10.1016/j.ahj.2014.06.017. Epub 2014 Jul 4. PMID: 25262270 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Coronary artery disease: Darapladib fails to improve the STABILITY of CAD. Roberts A. Nat Rev Cardiol. 2014 Jun;11(6):310. doi: 10.1038/nrcardio.2014.50. Epub 2014 Apr 15. PMID: 24736761

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, Moliterno DJ, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW. Am Heart J. 2014 Dec;168(6):869-77.e1. doi: 10.1016/j.ahj.2014.09.002. Epub 2014 Sep 16. PMID: 25458650 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• New antithrombotics for secondary prevention of acute coronary syndrome. Goto S, Tomita A. Clin Cardiol. 2014 Mar;37(3):178-87. doi: 10.1002/clc.22233. Epub 2014 Jan 22. PMID: 24452610 Review.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Darapladib for preventing ischemic events in stable coronary heart disease. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30. PMID: 24678955 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. Marathe GK, Pandit C, Lakshmikanth CL, Chaithra VH, Jacob SP, D'Souza CJ. J Lipid Res. 2014 Sep;55(9):1847-54. doi: 10.1194/jlr.R045492. Epub 2014 May 23. PMID: 24859738. Review.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9. PMID: 24402559 Clinical Trial.

  Morton, E. (Other)

  2014

  Activity: Other activity types › Other

• HREC Committee member (research)

  Buckley, L. (Participant)

  2013 → …

  Activity: Other activity types › Other

• Equity Trustees equipment grant

  Lavery, R. (Participant)

  2013

  Activity: Other activity types › Other

• Analytical evaluation of the GeneXpert® CT/NG, the first genetic point of care assay for simultaneous detection of Neisseria gonorrhoeae and Chlamydia trachomatis

  Tabrizi, S. (Participant), Unemo, M. (Participant), Golparian, D. (Participant), Twin, J. (Participant), Limnios, A. (Participant), Lahra, M. (Participant), Guy, R. (Participant) & Shephard, M. (Participant)

  14 Jul 2013 → 17 Jul 2013

  Activity: Other activity types › Other

• Skills for Collaboration, Behaviour Change & Managing Complexity: Building the Aged Care Workforce Capacity in Complex Care Coordination

  Lawn, S. (Participant)

  2013

  Activity: Other activity types › Other

• Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors. Wang K, Xu W, Zhang W, Mo M, Wang Y, Shen J. Bioorg Med Chem Lett. 2013 May 15;23(10):2897-901. doi: 10.1016/j.bmcl.2013.03.062. Epub 2013 Mar 26. PMID: 23575276

  Morton, E. (Other)

  2013

  Activity: Other activity types › Other

• Air Embolus During Clavicle Internal Fixation with a Plate. Australian Orthopaedic Association Newsletter. 2 March 1999

  Bain, G. (Participant), Eng, K. (Participant) & Zumstein, M. (Participant)

  2013

  Activity: Other activity types › Other

• Utility of Lp-PLA2 in lipid-lowering therapy. Racherla S, Arora R. Am J Ther. 2012 Mar;19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32. PMID: 20634673 Review.

  Morton, E. (Other)

  2012

  Activity: Other activity types › Other

• Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism? Duerschmied D, Bode C. Hamostaseologie. 2012;32(3):221-7. doi: 10.5482/HAMO-12-05-0006. Epub 2012 Jul 10. PMID: 22777302

  Morton, E. (Other)

  2012

  Activity: Other activity types › Other

• Vorapaxar expands antiplatelet options. Duerschmied D, Bode C. Hamostaseologie. 2012;32(3):221-227. doi: 10.5482/HAMO-12-05-0006. Epub 2017 Dec 28. PMID: 29589363 English.

  Morton, E. (Other)

  2012

  Activity: Other activity types › Other

• Volunteer Musician: Heart Foundation Fundraiser

  Downes, C. E. (Participant)

  Oct 2012

  Activity: Other activity types › Other

• Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13. PMID: 22077816 Clinical Trial.

  Morton, E. (Other)

  2012

  Activity: Other activity types › Other

• Graduate Of Australian Institute of Company Directors

  Kennedy, E. (Participant)

  2011

  Activity: Other activity types › Other

• Clinical Laboratory Leadership and Management Certificate Program

  Matthews, S. (Participant)

  30 Jun 2010 → 1 Jul 2011

  Activity: Other activity types › Other

• Equity of bowel cancer screening: An epidemiological and qualitative Study. Final Report. 2010.

  Ward, P. (Other), Javanparast, S. (Other), Ah Matt, M. (Other), Cole, S. R. (Other), Aylward, P. (Other), Gill, T. (Other), Martini, A. (Other), Wilson, C. (Other), Baratiny, G. (Other), Misan, G. (Other), Tsourtos, G. (Other), Young AM FTSE FAHMS AGAF, G. P. (Other) & Waite, J. (Other)

  2010

  Activity: Other activity types › Other

• Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L. Am Heart J. 2010 Oct;160(4):655-61. doi: 10.1016/j.ahj.2010.07.006. PMID: 20934559 Clinical Trial.

  Morton, E. (Other)

  2010

  Activity: Other activity types › Other

• Extracellular phospholipases in atherosclerosis. Karabina SA, Gora S, Atout R, Ninio E. Biochimie. 2010 Jun;92(6):594-600. doi: 10.1016/j.biochi.2010.02.002. Epub 2010 Feb 12. PMID: 20153800 Review.

  Morton, E. (Other)

  2010

  Activity: Other activity types › Other

• Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. Riley RF, Corson MA. IDrugs. 2009 Oct;12(10):648-55. PMID: 19790016 Review.

  Morton, E. (Other)

  2009

  Activity: Other activity types › Other